Jagsonpal Pharmaceuticals Ltd

AI
Jagsonpal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents
AI

Jagsonpal Pharmaceuticals Ltd

₹ 231 3.52%
28 Oct - close price
jagsonpal.com BSE: 507789 NSE: JAGSNPHARM
About

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Key Points

Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands

Website BSE NSE
  • Market Cap ₹ 1,526 Cr.
  • Current Price ₹ 231
  • High / Low ₹ 265 / 155
  • Stock P/E
  • Book Value ₹ 3.64
  • Dividend Yield 1.73 %
  • ROCE %
  • ROE %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 63.4 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2026
96
79
Operating Profit 17
OPM % 18%
2
Interest 0
Depreciation 2
Profit before tax 16
Tax % 25%
12
EPS in Rs 1.86
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Operating Profit
OPM %
Interest
Depreciation
Profit before tax
Tax %
EPS in Rs
Dividend Payout %
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: %
Stock Price CAGR
10 Years: 30%
5 Years: 27%
3 Years: 12%
1 Year: 4%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: %

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Equity Capital
Reserves
Total Liabilities
CWIP
Investments
Total Assets

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Net Cash Flow
Free Cash Flow
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit

Ratios

Consolidated / View Standalone

Debtor Days
Inventory Days
Days Payable
Cash Conversion Cycle
Working Capital Days
ROCE %

Insights

In beta
Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Brands Ranked in Top 5 (Molecule Category)
Count

Log in to view insights

Please log in to see hidden values.

Login
Medical Representatives (Field Force)
Count
New Product Launches
Count (Annual)
Distributors/Stockists (Dealers)
Count
Doctors/Prescribers Covered
Count
Stocking Points
Count
MR Productivity (PCPM)
Rs Lakh per MR per month
Top 10 Brand Revenue Concentration
% of Revenue

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

4 Recently
Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
68.48% 68.09% 68.04% 67.98% 67.82% 67.77% 67.65% 67.54% 67.39% 67.89% 69.06% 68.82%
0.53% 0.73% 1.10% 2.30% 2.10% 2.10% 2.17% 2.12% 2.12% 2.44% 2.30% 2.13%
0.82% 0.84% 0.84% 0.11% 0.00% 0.00% 0.05% 0.08% 0.15% 0.22% 0.62% 1.64%
30.16% 30.33% 30.01% 29.63% 30.10% 30.11% 30.12% 30.25% 30.34% 29.44% 28.04% 27.40%
No. of Shareholders 15,78516,28215,74815,63318,47121,08522,89924,65324,89526,26424,18126,537

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls